BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1529 related articles for article (PubMed ID: 26615423)

  • 21. Stomatin-like protein 2 is overexpressed in epithelial ovarian cancer and predicts poor patient survival.
    Sun F; Ding W; He JH; Wang XJ; Ma ZB; Li YF
    BMC Cancer; 2015 Oct; 15():746. PubMed ID: 26487491
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intratumoral interleukin-6 predicts ascites formation in patients with epithelial ovarian cancer: A potential tool for close monitoring.
    Masoumi-Moghaddam S; Amini A; Wei AQ; Robertson G; Morris DL
    J Ovarian Res; 2015 Aug; 8():58. PubMed ID: 26282935
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression and prognostic significance of microRNA-451 in human epithelial ovarian cancer.
    Ling S; Ruiqin M; Guohong Z; Ying W
    Eur J Gynaecol Oncol; 2015; 36(4):463-8. PubMed ID: 26390704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long non-coding RNA CCAT1 promotes metastasis and poor prognosis in epithelial ovarian cancer.
    Cao Y; Shi H; Ren F; Jia Y; Zhang R
    Exp Cell Res; 2017 Oct; 359(1):185-194. PubMed ID: 28754469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long non-coding RNA CPS1-IT1 is a positive prognostic factor and inhibits epithelial ovarian cancer tumorigenesis.
    Wang YS; Ma LN; Sun JX; Liu N; Wang H
    Eur Rev Med Pharmacol Sci; 2017 Jul; 21(14):3169-3175. PubMed ID: 28770969
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased expression of protein kinase CK2α correlates with poor patient prognosis in epithelial ovarian cancer.
    Ma Z; Wang X; He J; Xia J; Li Y
    PLoS One; 2017; 12(3):e0174037. PubMed ID: 28355289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MicroRNA‑455 inhibits cell proliferation and invasion of epithelial ovarian cancer by directly targeting Notch1.
    Xu L; Li H; Su L; Lu Q; Liu Z
    Mol Med Rep; 2017 Dec; 16(6):9777-9785. PubMed ID: 29039517
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stonin 2 Overexpression is Correlated with Unfavorable Prognosis and Tumor Invasion in Epithelial Ovarian Cancer.
    Sun X; Zhang W; Li H; Niu C; Ou Y; Song L; Zhang Y
    Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28758939
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CEP55 promotes epithelial-mesenchymal transition in renal cell carcinoma through PI3K/AKT/mTOR pathway.
    Chen H; Zhu D; Zheng Z; Cai Y; Chen Z; Xie W
    Clin Transl Oncol; 2019 Jul; 21(7):939-949. PubMed ID: 30607788
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dickkopf-4 is frequently overexpressed in epithelial ovarian carcinoma and promotes tumor invasion.
    Wang S; Wei H; Zhang S
    BMC Cancer; 2017 Jun; 17(1):455. PubMed ID: 28666421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aberrant TIMELESS expression is associated with poor clinical survival and lymph node metastasis in early-stage cervical carcinoma.
    Zhang W; He W; Shi Y; Zhao J; Liu S; Zhang F; Yang J; Xie C; Zhang Y
    Int J Oncol; 2017 Jan; 50(1):173-184. PubMed ID: 27909716
    [TBL] [Abstract][Full Text] [Related]  

  • 32. S100A7 Regulates Ovarian Cancer Cell Metastasis and Chemoresistance Through MAPK Signaling and Is Targeted by miR-330-5p.
    Lin M; Xia B; Qin L; Chen H; Lou G
    DNA Cell Biol; 2018 May; 37(5):491-500. PubMed ID: 29485916
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low levels of ADAM23 expression in epithelial ovarian cancer are associated with poor survival.
    Ma R; Tang Z; Sun K; Ye X; Cheng H; Chang X; Cui H
    Pathol Res Pract; 2018 Aug; 214(8):1115-1122. PubMed ID: 29921495
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
    Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
    BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NEDD9 overexpression is associated with the progression of and an unfavorable prognosis in epithelial ovarian cancer.
    Wang H; Mu X; Zhou S; Zhang J; Dai J; Tang L; Xiao L; Duan Z; Jia L; Chen S
    Hum Pathol; 2014 Feb; 45(2):401-8. PubMed ID: 24439227
    [TBL] [Abstract][Full Text] [Related]  

  • 36. LncRNA HOXD-AS1 promotes epithelial ovarian cancer cells proliferation and invasion by targeting miR-133a-3p and activating Wnt/β-catenin signaling pathway.
    Zhang Y; Dun Y; Zhou S; Huang XH
    Biomed Pharmacother; 2017 Dec; 96():1216-1221. PubMed ID: 29239819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. miR-215 functions as a tumor suppressor in epithelial ovarian cancer through regulation of the X-chromosome-linked inhibitor of apoptosis.
    Ge G; Zhang W; Niu L; Yan Y; Ren Y; Zou Y
    Oncol Rep; 2016 Mar; 35(3):1816-22. PubMed ID: 26676658
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CKS2 promotes tumor progression and metastasis and is an independent predictor of poor prognosis in epithelial ovarian cancer.
    Xu JH; Wang Y; Xu D
    Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3225-3234. PubMed ID: 31081074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mir-595 is a significant indicator of poor patient prognosis in epithelial ovarian cancer.
    Zhou QH; Zhao YM; Jia LL; Zhang Y
    Eur Rev Med Pharmacol Sci; 2017 Oct; 21(19):4278-4282. PubMed ID: 29077170
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The conglomeration of diagnostic, prognostic and therapeutic potential of serum miR-199a and its association with clinicopathological features in epithelial ovarian cancer.
    Zuberi M; Khan I; Gandhi G; Ray PC; Saxena A
    Tumour Biol; 2016 Aug; 37(8):11259-66. PubMed ID: 26951510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 77.